Table 1 Patient characteristics
From: Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors
Patient | Progression time: time to metastasis (months) | Age at primary | Tumor size (cm) | Histology | Fuhrman grade | Gender | Metastasis location |
|---|---|---|---|---|---|---|---|
1 | 6 | 51 | 5 | Clear Cell | 3 | M | Lung |
2 | 72 | 64 | 3.2 | Clear Cell | 3 | M | Lung |
3 | 6 | 50 | 10 | Clear Cell | 3 | M | Abdominal Wall |
4 | 12 | 45 | 7 | Clear Cell | 3 | M | Skin |
5 | 12 | 70 | 4 | Clear Cell | 2 | M | Lung |
6 | 6 | 58 | 3 | Clear Cell | 2 | F | Colon |
7 | 24 | 17 | 13 | Clear Cell | 3 | F | Lung |
8 | 36 | 66 | 4 | Clear Cell | 2 | M | Lung |
9 | 24 | 64 | 10.7 | Clear Cell | 3 | M | Liver |
10 | 48 | 69 | 6 | Clear Cell | 3 | F | Skin |
11 | 36 | 61 | 8 | Clear Cell | 3 | F | Lung |
12 | 24 | 61 | 8 | Clear Cell | 3 | F | Liver |
13 | 36 | 68 | 4.5 | Clear Cell | 1 | M | Bone |
14 | 6 | 56 | 11 | Clear Cell | 3 | F | Pituitary |
15 | 120 | 47 | 8 | Clear Cell | 3 | M | Testes |
16 | 24 | 54 | 6.5 | Clear Cell | 2 | F | Soft Tissue |
17 | 48 | 62 | 10.5 | Clear Cell | 3 | M | Bone |
18 | 156 | 56 | 3.5 | Clear Cell | 3 | M | Lung |
19 | 108 | 59 | 8.5 | Clear Cell | 2 | M | Lung |
20 | 12 | 28 | 4 | Mixed | 3 | M | Lymph Node |
21 | 6 | 54 | Unknown | Clear Cell | 2 | M | Lung |
22 | 12 | 40 | 3.7 | Mixed | 4 | M | Lung |
23 | 6 | 64 | 3.5 | Clear Cell | 2 | M | Bone |
24 | 84 | 46 | 14.5 | Clear Cell | 2 | F | Lung |
25 | 36 | 55 | 8.5 | Clear Cell | 2 | M | Lung |
26 | 36 | 66 | 6.5 | Clear Cell | 2 | M | Adrenal |
27 | 132 | 72 | 5 | Clear Cell | 2 | F | Adrenal |
28 | 12 | 72 | 6 | Mixed | 3 | F | Soft Tissue |
29 | 6 | 52 | 3.5 | Clear Cell | 3 | F | Bone |
30 | 12 | 50 | 12 | Clear Cell | 2 | F | Skin |
31 | 6 | 33 | 3.5 | Clear Cell | 2 | M | Bone |
32 | 36 | 69 | 10.5 | Clear Cell | 3 | F | Bone |
33 | 12 | 62 | 6 | Clear Cell | 3 | M | Bone |
34 | 36 | 47 | 8 | Clear Cell | 3 | F | Lung |